FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to infectious diseases, and can be used for differential diagnosis of hemostasis disorders in leptospirosis. Method includes determining after detection of clinical signs of leptospirosis the number of platelets (Pl), prothrombin index (PTI), the content of fibrinogen, activated partial thromboplastin time (APTT), platelet aggregation area (Spa), ristomycin-cofactor activity of von Willebrand factor (WF), level of soluble fibrin monomer complexes (SFMC). Then, based on the specified parameters: x1 – Pl; x2 – PTI; x3 – Fibrinogen; x4 – APTT; x5 – Spa; x6 – WF; x7 – SFMC by formulas, determine the variants of hemostasis disorders, (G): G1=-164.757+21.366x1+61.182x2+1.615x3+52.351x4+38.425x5+121.727x6+3.788x7; G2=-165.085+10.751x1+65.915x2-1.212x3+51.486x4+53.008x5+105.692x6+0.728x7; G3=-139.836+56.347x1+77.306x2-0.959x3+47.539x4+27.875x5+96.970x6+0.669x7; G4=-123.808+50.170x1+49.304x2-1.889x3+52.638x4+29.901x5+95.247x6+1.845x7; G5=-186.544+35.336x1+68.731x2-1.355x3+48.172x4+25.020x5+146.688x6+1.605x7, where among the values of G1, … G5 select G with the highest value corresponding to the variant of hemostasis disorder: G1 – corresponds to a syndrome of disseminated intravascular blood coagulation (DIC-syndrome); G2 – isolated thrombocytopenia (IT), G3 – absence of coagulopathy, G4 – a hepatic variant of coagulopathy, G5 – uremic variant of hemostasis disturbance.
EFFECT: use of the invention makes it possible to shorten the time for interpreting laboratory studies, individualize further therapeutic tactics.
1 cl, 4 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF DETERMINING FACTORS OF PREDICTION OF SEVERE HEMORRHAGIC COMPLICATIONS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA IN DIAGNOSTICS | 2009 |
|
RU2400750C1 |
METHOD FOR PREDICTING NONTHROMBOGENIC COMPLICATIONS IN POSTOPERATIVE PERIOD | 2001 |
|
RU2218573C2 |
METHOD FOR PREDICTION OF HIGH RISK OF SEVERE COVID-19 | 2022 |
|
RU2787517C1 |
METHOD FOR PREVENTING AND TREATING INTRA- AND POSTOPERATIVE PARENCHYMAL HEMORRHAGE IN COMBINED LUNG OPERATIONS WITH PARTIAL OR TOTAL COSTAL PLEURECTOMY IN PATIENTS WITH INITIAL RISK OF DEVELOPING VENOUS THROMBOEMBOLIC COMPLICATIONS | 2019 |
|
RU2710232C1 |
METHOD OF HEMODIALYSIS AT PATIENTS WITH RISK OF BLEEDING | 2004 |
|
RU2343936C2 |
METHOD FOR DETERMINING EARLY PREDICTORS OF ONSET OF DIFFERENTIATION SYNDROME IN TREATING PATIENTS SUFFERING ACUTE PROMYELOCYTE LEUKEMIA | 2011 |
|
RU2461003C1 |
METHOD OF DIFFERENTIAL DIAGNOSTICS OF ACUTE AND SUBACUTE INFECTIOUS ENDOCARDITIS ACCORDING TO IMMUNE INDICATOR | 2017 |
|
RU2675264C1 |
METHOD OF GLOBULAR BLOOD VOLUME CONTROL AND IMMUNOMODULATION ACCOMPANYING TRANSPLANTATION | 2011 |
|
RU2452519C1 |
METHOD FOR TREATING TUBERCULOSIS | 2004 |
|
RU2269346C1 |
METHOD FOR EXTRACORPOREAL INDIRECT ELECTROCHEMICAL BLOOD OXIDATION WITH 0,06 % SODIUM HYPOCHLORITE IN PATIENTS WITH INFECTIOUS-INFLAMMATORY DISEASES OF URINARY ORGANS AND DEGREE 1 ENDOTOXICOSIS | 2013 |
|
RU2522221C1 |
Authors
Dates
2018-07-03—Published
2017-08-21—Filed